Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
August 06, 2024 02:30 ET
|
Abivax
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the...
Abivax Provides Operational and Key Program Update
July 15, 2024 16:00 ET
|
Abivax
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
Sitryx announces leadership transition
July 02, 2024 07:00 ET
|
Sitryx Therapeutics
Sitryx announces leadership transition Iain Kilty appointed Chief Executive Officer Neil Weir to assume role of President and remain on Board of Directors Oxford, UK – 2 July 2024 – Sitryx...
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
June 04, 2024 16:10 ET
|
Abivax
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
May 15, 2024 08:35 ET
|
ZyVersa Therapeutics
ZyVersa is on track to achieve key development milestones over the next 3 quarters.
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
May 08, 2024 02:30 ET
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Abivax reports 2023 financial results and operational update
April 02, 2024 02:30 ET
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development
March 04, 2024 07:00 ET
|
Sitryx Therapeutics
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development Ben Stephens brings seasoned operational and...
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
February 02, 2024 02:30 ET
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024 02:30 ET
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...